BIO Names Jeanne Haggerty as Senior Vice President for Federal Government Relations

WASHINGTON--(BUSINESS WIRE)--Jim Greenwood, President & CEO of the Biotechnology Industry Organization (BIO), today announced the appointment of Jeanne Haggerty as Senior Vice President of Federal Government Relations. She will report to Fritz Bittenbender, Executive Vice President, Public Affairs.

"For nearly a decade, Jeanne has played a valuable and vital role in shaping and executing BIO's legislative efforts on the Hill," Greenwood said. "She is respected by members and staff for her deep understanding of our industry and her ability to translate that knowledge into effective and pragmatic public policy."

In her new role, Haggerty will serve as the lead in-house lobbyist for BIO and will oversee the organization's federal government relations work across its Health, Industrial and Environmental and Food & Agriculture sectors.

Haggerty joined BIO in September 2006 as Director for Federal Government Relations and was named Vice President in September 2014.

Prior to joining BIO, Haggerty served as a Professional Staff Member for the House Committee on Energy and Commerce. She also worked for Senator Chuck Grassley (R-IA) on the Senate Aging Committee, for the Senate Finance Committee and in government relations at Epstein, Becker and Green.

Haggerty graduated from the University of Vermont.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter." Subscribe to the BIO Newsletter.


Biotechnology Industry Organization
George Goodno, 202-962-6660
Twitter: @IAmBiotech

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.